Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY's Julian Graves acquisition clears

This article was originally published in The Tan Sheet

Executive Summary

U.K. regulators July 22 clear supplement firm NBTY's acquisition of 350-store U.K. confectionery chain Julian Graves. The OK followed provisional findings by the Competition Commission, the Ronkonkoma, N.Y.-based firm said. The firm purchased Julian Graves in September for $25 million, but the commission raised concerns the acquisition could obstruct competition in the market for seeds, nuts and dried fruit (1"The Tan Sheet" July 20, 2009). NBTY said it expects the commission to make a final decision before Sept. 4

You may also be interested in...



NBTY Not "Trigger Happy," But Acquisitions Stay In Its Crosshairs

NBTY hopes to remain a supplement industry giant in part by continuing to acquire other businesses, a strategy with an improving outlook as opportunities emerge during the global economic slump

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

China Planning To Ban Gene Editing Technology Exports

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel